Efectos secundarios del tratamiento para la leucemia linfoblástica aguda .. ( PEG-L asparaginasa; Oncaspar®) administrada por inyección. O Vincristina. L-asparaginase, definition: alkylating anticancer drug used in the treatment of L -asparaginasa, definition: fármaco alquilante antineoplásico, utilizado para el Los efectos secundarios más comunes son nauseas, vómitos. y otros efectos adversos de este grupo de fármacos, ya que estos pacientes los efectos citotóxicos de la quimioterapia son mediados por diversos . Actinomicina D, metotrexato, andrógenos, L-asparaginasa, procarbazina, vincristina.

Author: Brall Faucage
Country: Switzerland
Language: English (Spanish)
Genre: Video
Published (Last): 19 October 2009
Pages: 334
PDF File Size: 14.80 Mb
ePub File Size: 20.35 Mb
ISBN: 883-2-24558-370-5
Downloads: 50848
Price: Free* [*Free Regsitration Required]
Uploader: Kazilkree

Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible. Known allergy to any of the adversis used in the study. Los sujetos deben haber finalizado todo tipo de inmunoterapia activa p.

l-asparaginasa efectos adversos pdf

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Time to toxicity will be evaluated to differentiate single-agent carfilzomib from carfilzomib in combination with induction chemotherapy? Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.

Trials with results Trials without results. Son aptos los sujetos que hayan sufrido una alergia previa a la asparaginasa PEG pero que puedan recibir Erwinia.


For these items you should use the filters and not add them to your search terms in the text field. Adequate liver function, defined as both of the following: Phase 1b – To assess the safety and tolerability of carfilzomib, alone and in combination with induction chemotherapy, for the treatment of children with relapsed or refractory acute l-asparzginasa leukemia ALL -To determine the maximum tolerated dose MTD of carfilzomib in combination with induction chemotherapy.

The duration of this interval must be approved by the Onyx study medical efecgos.

Medicinas para Quimioterapia – Nombres de Medicina

The IMP has been designated in this indication as an orphan drug in the Community. A group of cancers that usually begins in the bone marrow and results in high numbers of abnormal white blood cells. Relapsed or Refractory Acute Lymphoblastic Leukemia. Date on which this record was first entered in l-asparagonasa EudraCT database:. Committee on Advanced therapies CAT has issued a classification for this product.

Both Female Only Male Only.

Combination product that includes a device, but does not involve an Advanced Therapy. Subjects are under 18 years old. IMP with orphan designation in erectos indication.

Active treatment for graft-versus-host disease 6. Karnofsky or Lansky scores?

EU Clinical Trials Register. Review by the Competent Authority or Ethics Committee in the country concerned.


Clinical trials

Known allergy to Captisol a cyclodextrin derivative used to solubilize carfilzomib; for a complete listing of Captisol-enabled drugs, see the Ligand Pharmaceuticals, Inc. Trials with results Trials without results Clear advanced search filters. How to search [pdf]. Subjects must have a serum creatinine level that is?

The trial involves single site in the Member State concerned. Restricciones de tratamientos previos: For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. Subjects must have fully recovered from l-asparagunasa acute toxic effects of all previous chemotherapy, immunotherapy, or radiotherapy treatment before enrollment.

Title of the trial for lay people, in easily understood, i. Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name. Pneumonia AND sponsor name. Age 18 years or younger at the time of study treatment initiation.

Positive l-asparaginqsa for bacteria or fungus within 14 days of the initiation of therapy 7. Clear advanced search filters.